Aromastase Inhibitor Therapy For Symptomatic Uterine Leimyomata In Premenopausal Women | ||||
| The Egyptian Journal of Fertility of Sterility | ||||
| Article 7, Volume 15, Issue 2 - Serial Number 11106352, December 2011, Page 29-33 PDF (1.83 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/egyfs.2011.257273 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Hanan A.A Ghal | ||||
| Department of Obstetrics and Gynecology, Faculty of medicine, Zagazig University | ||||
| Abstract | ||||
| Objective: To examine the effect of letrozole on symptomatic leiomyomata. Patients and Methods: In a prospective, intervention study , forty six premenopausal women with fifty two leiomyomata were invited to take 5 mg letrozole daily for 3 treatment cycles of 28 days each. Leiomyoma, uterine and ovarian volumes, endometrial thickness, gonadotrophins, and the scores of menstrual pictograms and Uterine Fibroid Symptom and Health Related Quality of Life (UFS – HRQoL) were recorded at the start and conclusion of this study. Results: Letrozole resulted in 53.29% mean reduction in original leiomyomata volumes (P < 0.01) without significant reduction in myoma free uterine tissue. Estradiol levels dropped significantly from baseline levels (64.32 + 16.77) (mean + SD) to (40.83 + 12.032) pg/ml (p < 0.001) at the end of this study. Conclusion: Adding to its significant shrinkage of leiomyomta, letrozole improved leiomyoma related symptomology, quality of life and menstrual pattern significantly. | ||||
|
Statistics Article View: 57 PDF Download: 29 |
||||
